

Use of Daptomycin in the Treatment of Spinal Infections

S Antony, L Tiscareno-Grajeda

Citation

S Antony, L Tiscareno-Grajeda. *Use of Daptomycin in the Treatment of Spinal Infections*. The Internet Journal of Infectious Diseases. 2009 Volume 9 Number 1.

Abstract

Daptomycin is a lipopeptide antibiotic that is active against most Gram-positive bacteria including methicillin-resistant *Staphylococcus aureus* (MRSA) (1). This is an observational study using daptomycin in the treatment of spinal/laminectomy infections with and without instrument removal. The objective of this study was to evaluate the use of daptomycin against gram-positive bacteria, including resistant isolates in spinal infections.

INTRODUCTION

Daptomycin is a lipopeptide antibiotic that is active against most Gram-positive bacteria including methicillin-resistant *Staphylococcus aureus* (MRSA) (1). This is an observational study using daptomycin in the treatment of spinal/laminectomy infections with and without instrument removal. The objective of this study was to evaluate the use of daptomycin against gram-positive bacteria, including resistant isolates in spinal infections.

METHODS

A prospective observational study was conducted for all patients (N=16) treated by the authors with daptomycin as either primary choice of treatment, or after failed previous antimicrobial agents for spinal infections. Data collected included demographic patient information, duration of therapy, surgical procedures, pathogen, side effects if any, and clinical outcomes.

RESULTS

Pathogens included methicillin-resistant *Staphylococcus aureus* (N=7); methicillin-sensitive *Staphylococcus aureus* (N=5); vancomycin-resistant *Enterococcus*/methicillin-sensitive *Staphylococcus aureus* (N=1); alpha *Streptococcus* (N=1), and negative culture (N=2). After a follow-up of 6-12 months, 14 patients (87%) had no clinical, laboratory, or radiographic signs of recurrence. Of these, 4 did not require surgical intervention. Two patients (12%) failed therapy with daptomycin. These two patients grew MRSA. Ten (62%) patients had received previous antimicrobial therapy and two of these failed therapy when treated with daptomycin. Previously used antimicrobials included vancomycin (N=5),

cephalosporin (N=4), ampicillin (N=1).

Thirteen patients had lumbar infections with a 81% cure rate; 2 patients had cervical infections with a 100% cure rate; one pt died of other co- morbidities, and the other patient with thoracic infection failed daptomycin therapy. Relatively immunosuppressed patients (N=8) had a failure rate of 50%. No side effects were noted to daptomycin therapy regimen during this study. Twelve patients received daptomycin at dosages of 6 mg/kg/day; mean therapy duration was 41 days (range 14-48). Daptomycin therapy was successful in 87% (14/16) of patients, as determined by clinical, laboratory, or radiographic signs of recurrence.

Treatment of spinal/orthopedic infections including prosthetic joint infections are limited with the number of antibiotics available (2) Vancomycin has been the mainstay for several years but there has never been any good data available to assess the outcome of these infections treated with vancomycin. (3,4) In addition, vancomycin is slowly bactericidal and its penetration into the bone is debatable. This study looked at patients with osteomyelitis of the vertebrae as well as epidural infections with MRSA/MRSE with and without hardware.

CONCLUSIONS

Preliminary evidence suggests that daptomycin appears to be a good alternative to vancomycin in the treatment of infected spinal procedures although removal of the infected hardware in addition to antimicrobial therapy will remain the cornerstone for permanent cure especially for MRSA/MRSE and VRE. Further large scale studies assessing the efficacy of this drug with and without retained hardware would be

useful.

References

1. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. *Clin Infect Dis* 2004;38:994–1000.
2. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. *Clin Infect Dis* 2001;33(suppl 2):S94-S106.
3. Bernard L, Hoffmeyer P, Assal M, et al. Trends in the treatment of orthopedic prosthetic infections. *J Antimicrob Chemother* 2004;53:127–29.
4. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment for experimental methicillin-resistant *Staphylococcus aureus* osteomyelitis in rabbits. *Antimicrob Agents Chemother* 1989;33:689–92.
5. Salgado CD, Dash S, Cantey JR, et al. Higher risk of failure of methicillin-resistant *Staphylococcus aureus* prosthetic joint infections. *Clin Orthop Relat Res* 2007;461:48-53.

Author Information

Suresh J. Antony, MD

Texas Tech University Health Sciences Center

L. Iliana Tiscareno-Grajeda, MD

William Beaumont Army Medical Center